Skip to main content

Merendino Lauren's Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed May 19, 2025

Accession no.
0001415889-25-013687
Filed
May 19, 2025
Trade date
May 15-16, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $24.6K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Merendino LaurenCIK 0001855298Officer (Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 15, 2025Common StockMOption exerciseAcquired+3,162––31,714Direct
May 15, 2025Common StockMOption exerciseAcquired+3,687––35,401Direct
May 15, 2025Common StockMOption exerciseAcquired+3,687––39,088Direct
May 16, 2025Common StockSSaleDisposed−3,927$6.26−$24,583.0235,161Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 15, 2025Common StockMOption exerciseDisposed−3,162$0.00$028,464Direct
May 15, 2025Common StockMOption exerciseDisposed−3,687$0.00$036,878Direct
May 15, 2025Common StockMOption exerciseDisposed−3,687$0.00$051,626Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)